EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Meridian Bioscience Stock Hits New 52-Week Low (VIVO)

By TheStreet Wire 08/19/11 - 03:39 PM EDT

Find out if (VIVO) is in Cramer's Portfolio.

NEW YORK (TheStreet) -- Meridian Bioscience (Nasdaq:VIVO) hit a new 52-week low Friday as it is currently trading at $16.81, below its previous 52-week low of $16.89 with 202,860 shares traded as of 3:17 p.m. ET. Average volume has been 297,300 shares over the past 30 days.

Meridian Bioscience has a market cap of $749.2 million and is part of the health care sector and drugs industry. Shares are down 24.4% year to date as of the close of trading on Thursday.

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The company has a P/E ratio of 29.4, above the average drugs industry P/E ratio of 29 and above the S&P 500 P/E ratio of 17.7.

Practice your VIVO trading strategies and win cash in our stock game.

TheStreet Ratings rates Meridian Bioscience as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and increase in net income. However, as a counter to these strengths, we also find weaknesses including premium valuation and relatively poor performance when compared with the S&P 500 during the past year. You can view the full Meridian Bioscience Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

For more information on Meridian Bioscience Inc. click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.